Erratum: Tau Kinetics in Neurons and the Human Central Nervous System (Neuron (2018) 97(6) (1284–1298.e7)(S0896627318301363)(10.1016/j.neuron.2018.02.015));Tau Kinetics in Neurons and the Human Central Nervous System

Neuron

Volumn 97, Issue 6, 2018, Pages 1284-1298.e7

  Sato, Chihiro ^a   Barthélemy, Nicolas R ^a   Mawuenyega, Kwasi G ^a   Patterson, Bruce W ^a   Gordon, Brian A ^a   Jockel Balsarotti, Jennifer ^a   Sullivan, Melissa ^a   Crisp, Matthew J ^a   Kasten, Tom ^a   Kirmess, Kristopher M ^a   Kanaan, Nicholas M ^b   Yarasheski, Kevin E ^a   Baker Nigh, Alaina ^a   Benzinger, Tammie L S ^a   Miller, Timothy M ^a   Karch, Celeste M ^a   Bateman, Randall J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid; human; induced pluripotent stem cell; isoform; PET; phosphorylation; positron emission tomography; production rate; SILK; stable isotope labeling kinetics; tau

Indexed keywords

TAU PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; ISOTOPE LABELING; KINETICS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; TURNOVER TIME; VERY ELDERLY; AMINO ACID SEQUENCE; BRAIN; CELL CULTURE; CELL LINE; CEREBROSPINAL FLUID; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BIOMARKERS; BRAIN; CELL LINE; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KINETICS; MALE; MIDDLE AGED; TAU PROTEINS;

EID: 85044160198     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2018.04.035     Document Type: Erratum

References (80)

1. Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., Hutton, M., Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8 (1999), 711–715.
2. Ban, H., Nishishita, N., Fusaki, N., Tabata, T., Saeki, K., Shikamura, M., Takada, N., Inoue, M., Hasegawa, M., Kawamata, S., Nishikawa, S., Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. USA 108 (2011), 14234–14239.
3. Barthélemy, N.R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., Becher, F., Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J. Proteome Res. 15 (2016), 667–676.
4. Barthélemy, N.R., Bateman, R.J., Marin, P., Becher, F., Sato, C., Lehmann, S., Gabelle, A., Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-β pathology. bioRxiv, 2017, 10.1101/226977.
5. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., Holtzman, D.M., Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12 (2006), 856–861.
6. Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., et al., Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367 (2012), 795–804.
7. Biernat, J., Gustke, N., Drewes, G., Mandelkow, E.M., Mandelkow, E., Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11 (1993), 153–163.
8. Borroni, B., Gardoni, F., Parnetti, L., Magno, L., Malinverno, M., Saggese, E., Calabresi, P., Spillantini, M.G., Padovani, A., Di Luca, M., Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging 30 (2009), 34–40.
9. Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16 (1995), 271–278 discussion 278–284.
10. Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci. Transl. Med., 8, 2016, 338ra66.
11. Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., Griswold-Prenner, I., Human secreted tau increases amyloid-beta production. Neurobiol. Aging 36 (2015), 693–709.
12. Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., Hof, P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000), 95–130.
13. Cairns, N.J., Bigio, E.H., Mackenzie, I.R.A., Neumann, M., Lee, V.M.-Y., Hatanpaa, K.J., White, C.L. 3rd, Schneider, J.A., Grinberg, L.T., Halliday, G., et al., Consortium for Frontotemporal Lobar Degeneration. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114 (2007), 5–22.
14. Carmel, G., Mager, E.M., Binder, L.I., Kuret, J., The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 271 (1996), 32789–32795.
15. Chai, X., Dage, J.L., Citron, M., Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 48 (2012), 356–366.
16. Combs, B., Hamel, C., Kanaan, N.M., Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies. Neurobiol. Dis. 94 (2016), 18–31.
17. Crisp, M.J., Mawuenyega, K.G., Patterson, B.W., Reddy, N.C., Chott, R., Self, W.K., Weihl, C.C., Jockel-Balsarotti, J., Varadhachary, A.S., Bucelli, R.C., et al. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J. Clin. Invest. 125 (2015), 2772–2780.
18. de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, G.A., et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73 (2012), 685–697.
19. Derisbourg, M., Leghay, C., Chiappetta, G., Fernandez-Gomez, F.-J., Laurent, C., Demeyer, D., Carrier, S., Buée-Scherrer, V., Blum, D., Vinh, J., et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci. Rep., 5, 2015, 9659.
20. Desikan, R.S., Schork, A.J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L.K., Holland, D., Brewer, J.B., Chen, C.-H., Thompson, W.K., et al., ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol. Psychiatry 20 (2015), 1588–1595.
21. DeVos, S.L., Goncharoff, D.K., Chen, G., Kebodeaux, C.S., Yamada, K., Stewart, F.R., Schuler, D.R., Maloney, S.E., Wozniak, D.F., Rigo, F., et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33 (2013), 12887–12897.
22. DeVos, S.L., Miller, R.L., Schoch, K.M., Holmes, B.B., Kebodeaux, C.S., Wegener, A.J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9 (2017), 1–10.
23. Dickson, D.W., Kouri, N., Murray, M.E., Josephs, K.A., Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45 (2011), 384–389.
24. Ehrlich, M., Hallmann, A.-L., Reinhardt, P., Araúzo-Bravo, M.J., Korr, S., Röpke, A., Psathaki, O.E., Ehling, P., Meuth, S.G., Oblak, A.L., et al. Distinct neurodegenerative changes in an induced pluripotent stem cell model of frontotemporal dementia linked to mutant TAU protein. Stem Cell Reports 5 (2015), 83–96.
25. Fagan, A.M., Xiong, C., Jasielec, M.S., Bateman, R.J., Goate, A.M., Benzinger, T.L.S., Ghetti, B., Martins, R.N., Masters, C.L., Mayeux, R., et al., Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci. Transl. Med., 6, 2014, 226ra30.
26. Ferreira, A., Caceres, A., Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules. J. Neurosci. 11 (1991), 392–400.
27. Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33 (2002), 341–355.
28. Fitzpatrick, A.W.P., Falcon, B., He, S., Murzin, A.G., Murshudov, G., Garringer, H.J., Crowther, R.A., Ghetti, B., Goedert, M., Scheres, S.H.W., Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547 (2017), 185–190.
29. Frost, B., Jacks, R.L., Diamond, M.I., Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284 (2009), 12845–12852.
30. Funk, K.E., Mirbaha, H., Jiang, H., Holtzman, D.M., Diamond, M.I., Distinct therapeutic mechanisms of Tau antibodies: promoting microglial clearance versus blocking neuronal uptake. J. Biol. Chem. 290 (2015), 21652–21662.
31. Gordon, B.A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D.M., Cairns, N.J., et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 139 (2016), 2249–2260.
32. Guillozet-Bongaarts, A.L., Garcia-Sierra, F., Reynolds, M.R., Horowitz, P.M., Fu, Y., Wang, T., Cahill, M.E., Bigio, E.H., Berry, R.W., Binder, L.I., Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 26 (2005), 1015–1022.
33. Haase, C., Stieler, J.T., Arendt, T., Holzer, M., Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. Neurochem. 88 (2004), 1509–1520.
34. Hampel, H., Blennow, K., Shaw, L.M., Hoessler, Y.C., Zetterberg, H., Trojanowski, J.Q., Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45 (2010), 30–40.
35. Hanger, D.P., Betts, J.C., Loviny, T.L., Blackstock, W.P., Anderton, B.H., New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71 (1998), 2465–2476.
36. Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., Blennow, K., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297 (2001), 187–190.
37. Horowitz, P.M., Patterson, K.R., Guillozet-Bongaarts, A.L., Reynolds, M.R., Carroll, C.A., Weintraub, S.T., Bennett, D.A., Cryns, V.L., Berry, R.W., Binder, L.I., Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J. Neurosci. 24 (2004), 7895–7902.
38. Horowitz, P.M., LaPointe, N., Guillozet-Bongaarts, A.L., Berry, R.W., Binder, L.I., N-terminal fragments of tau inhibit full-length tau polymerization in vitro. Biochemistry 45 (2006), 12859–12866.
39. Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q., Lee, V.M.-Y., Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33 (2013), 1024–1037.
40. Kanmert, D., Cantlon, A., Muratore, C.R., Jin, M., O'Malley, T.T., Lee, G., Young-Pearse, T.L., Selkoe, D.J., Walsh, D.M., C-terminally truncated forms of Tau, but not full-length Tau or its C-terminal fragments, are released from neurons independently of cell death. J. Neurosci. 35 (2015), 10851–10865.
41. Karch, C.M., Jeng, A.T., Goate, A.M., Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem. 287 (2012), 42751–42762.
42. Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M., Diamond, M.I., Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287 (2012), 19440–19451.
43. Liu, W.-K., Moore, W.T., Williams, R.T., Hall, F.L., Yen, S.-H., Application of synthetic phospho- and unphospho- peptides to identify phosphorylation sites in a subregion of the tau molecule, which is modified in Alzheimer's disease. J. Neurosci. Res. 34 (1993), 371–376.
44. Liu, L., Drouet, V., Wu, J.W., Witter, M.P., Small, S.A., Clelland, C., Duff, K., Trans-synaptic spread of tau pathology in vivo. PLoS ONE, 7, 2012, e31302.
45. Liu, C., Song, X., Nisbet, R., Götz, J., Co-immunoprecipitation with Tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2N Tau in disease. J. Biol. Chem. 291 (2016), 8173–8188.
46. Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., Paul, S.M., Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep., 5, 2015, 11161.
47. Mair, W., Muntel, J., Tepper, K., Tang, S., Biernat, J., Seeley, W.W., Kosik, K.S., Mandelkow, E., Steen, H., Steen, J.A., FLEXITau: quantifying post-translational modifications of Tau protein in vitro and in human disease. Anal. Chem. 88 (2016), 3704–3714.
48. Mandelkow, E.-M., Stamer, K., Vogel, R., Thies, E., Mandelkow, E., Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24 (2003), 1079–1085.
49. McAvoy, T., Lassman, M.E., Spellman, D.S., Ke, Z., Howell, B.J., Wong, O., Zhu, L., Tanen, M., Struyk, A., Laterza, O.F., Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem. 60 (2014), 683–689.
50. Meredith, J.E. Jr., Sankaranarayanan, S., Guss, V., Lanzetti, A.J., Berisha, F., Neely, R.J., Slemmon, J.R., Portelius, E., Zetterberg, H., Blennow, K., et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS ONE, 8, 2013, e76523.
51. Mishra, S., Gordon, B.A., Su, Y., Christensen, J., Friedrichsen, K., Jackson, K., Hornbeck, R., Balota, D.A., Cairns, N.J., Morris, J.C., et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neuroimage 161 (2017), 171–178.
52. Morita, T., Sobue, K., Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J. Biol. Chem. 284 (2009), 27734–27745.
53. Papasozomenos, S.C., Binder, L.I., Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil. Cytoskeleton 8 (1987), 210–226.
54. Patterson, B.W., Elbert, D.L., Mawuenyega, K.G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 78 (2015), 439–453.
55. Pooler, A.M., Phillips, E.C., Lau, D.H.W., Noble, W., Hanger, D.P., Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14 (2013), 389–394.
56. Pooler, A.M., Noble, W., Hanger, D.P., A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology 76:Pt A (2014), 1–8.
57. Portelius, E., Hansson, S.F., Tran, A.J., Zetterberg, H., Grognet, P., Vanmechelen, E., Höglund, K., Brinkmalm, G., Westman-Brinkmalm, A., Nordhoff, E., et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J. Proteome Res. 7 (2008), 2114–2120.
58. Potter, R., Patterson, B.W., Elbert, D.L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med., 5, 2013, 189ra77.
59. Price, J.C., Guan, S., Burlingame, A., Prusiner, S.B., Ghaemmaghami, S., Analysis of proteome dynamics in the mouse brain. Proc. Natl. Acad. Sci. USA 107 (2010), 14508–14513.
60. Rousset, O.G., Ma, Y., Evans, A.C., Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 39 (1998), 904–911.
61. Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A., Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82 (2014), 1271–1288.
62. Silva, M.C., Cheng, C., Mair, W., Almeida, S., Fong, H., Biswas, M.H.U., Zhang, Z., Huang, Y., Temple, S., Coppola, G., et al. Human iPSC-derived neuronal model of Tau-A152T frontotemporal dementia reveals Tau-mediated mechanisms of neuronal vulnerability. Stem Cell Reports 7 (2016), 325–340.
63. Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 47 (2001), 1776–1781.
64. Sposito, T., Preza, E., Mahoney, C.J., Setó-Salvia, N., Ryan, N.S., Morris, H.R., Arber, C., Devine, M.J., Houlden, H., Warner, T.T., et al. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Hum. Mol. Genet. 24 (2015), 5260–5269.
65. Stoothoff, W.H., Johnson, G.V.W., Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 1739 (2005), 280–297.
66. Su, Y., D'Angelo, G.M., Vlassenko, A.G., Zhou, G., Snyder, A.Z., Marcus, D.S., Blazey, T.M., Christensen, J.J., Vora, S., Morris, J.C., et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE, 8, 2013, e73377.
67. Su, Y., Blazey, T.M., Snyder, A.Z., Raichle, M.E., Marcus, D.S., Ances, B.M., Bateman, R.J., Cairns, N.J., Aldea, P., Cash, L., et al., Dominantly Inherited Alzheimer Network. Partial volume correction in quantitative amyloid imaging. Neuroimage 107 (2015), 55–64.
68. Sun, Q., Gamblin, T.C., Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry 48 (2009), 6002–6011.
69. Szendrei, G.I., Lee, V.M.-Y., Otvos, L. Jr., Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J. Neurosci. Res. 34 (1993), 243–249.
70. Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
71. Toledo, J.B., Xie, S.X., Trojanowski, J.Q., Shaw, L.M., Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126 (2013), 659–670.
72. Trabzuni, D., Wray, S., Vandrovcova, J., Ramasamy, A., Walker, R., Smith, C., Luk, C., Gibbs, J.R., Dillman, A., Hernandez, D.G., et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum. Mol. Genet. 21 (2012), 4094–4103.
73. Wang, Y., Mandelkow, E., Tau in physiology and pathology. Nat. Rev. Neurosci. 17 (2016), 5–21.
74. Wu, J.W., Hussaini, S.A., Bastille, I.M., Rodriguez, G.A., Mrejeru, A., Rilett, K., Sanders, D.W., Cook, C., Fu, H., Boonen, R.A.C.M., et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19 (2016), 1085–1092.
75. Yamada, K., Cirrito, J.R., Stewart, F.R., Jiang, H., Finn, M.B., Holmes, B.B., Binder, L.I., Mandelkow, E.-M., Diamond, M.I., Lee, V.M.-Y., Holtzman, D.M., In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31 (2011), 13110–13117.
76. Yamada, K., Holth, J.K., Liao, F., Stewart, F.R., Mahan, T.E., Jiang, H., Cirrito, J.R., Patel, T.K., Hochgräfe, K., Mandelkow, E.-M., Holtzman, D.M., Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211 (2014), 387–393.
77. Yamada, K., Patel, T.K., Hochgräfe, K., Mahan, T.E., Jiang, H., Stewart, F.R., Mandelkow, E.-M., Holtzman, D.M., Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol. Neurodegener., 10, 2015, 55.
78. Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., Wozniak, D.F., Diamond, M.I., Holtzman, D.M., Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80 (2013), 402–414.
79. Yokoyama, J.S., Karch, C.M., Fan, C.C., Bonham, L.W., Kouri, N., Ross, O.A., Rademakers, R., Kim, J., Wang, Y., Höglinger, G.U., et al., International FTD-Genomics Consortium (IFGC). Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 133 (2017), 825–837.
80. Zempel, H., Dennissen, F.J.A., Kumar, Y., Luedtke, J., Biernat, J., Mandelkow, E.-M., Mandelkow, E., Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. J. Biol. Chem. 292 (2017), 12192–12207.